Perspective
Failing the Public Health — Rofecoxib, Merck, and the FDA
N Engl J Med 2004; 351:1707-1709October 21, 2004
- Article
On May 21, 1999, Merck was granted approval by the Food and Drug Administration (FDA) to market rofecoxib (Vioxx). On September 30, 2004, after more than 80 million patients had taken this medicine and annual sales had topped $2.5 billion, the company withdrew the drug because of an excess risk of myocardial infarctions and strokes. This represents the largest prescription-drug withdrawal in history, but had the many warning signs along the way been heeded, such a debacle could have been prevented.
Neither of the two major forces in this five-and-a-half-year affair — neither Merck nor the FDA — fulfilled its responsibilities to the public. The pivotal trial for rofecoxib involved 8076 patients with rheumatoid arthritis and demonstrated that this coxib had lower gastrointestinal toxicity than naproxen.1 Even though the drug was approved in 1999 on the basis of data submitted to the FDA, the data were not submitted to a peer-reviewed journal until the following year and did not appear in print until November 23, 2000, one and a half years after commercial approval had been granted. The cardiovascular data reported in that article were incomplete, in part because of incomplete ascertainment: the design and execution of the trial had not anticipated that untoward cardiovascular events might occur.1
It was not until February 8, 2001, that the FDA Arthritis Advisory Committee met to discuss concern about the potential cardiovascular risks associated with rofecoxib. It remains unclear why the FDA waited two years after its review and approval of rofecoxib to conduct this meeting. My colleagues and I reviewed the data from the meeting that were made publicly accessible and published an analysis of all the available data on rofecoxib and celecoxib on August 22, 2001.2 Our primary conclusion, based on the clear-cut excess number of myocardial infarctions associated with rofecoxib and the numerical, albeit not statistically significant, excess associated with celecoxib, was that “it is mandatory to conduct a trial specifically assessing cardiovascular risk and benefit of these agents.”2 Such a trial needed to be conducted in patients with established coronary artery disease, who frequently have coexisting osteoarthritis requiring medication and have the highest risk of further cardiovascular events. Given the very high coincidence of coronary disease and arthritis, this group may represent the largest segment of the population for whom rofecoxib was prescribed. In light of the insight that arterial inflammation is the basis for myocardial infarction and stroke and the knowledge that coxibs reduce the production of biomarkers of inflammation such as C-reactive protein and improve endothelial function, such a trial would also have been quite attractive from the standpoint of potential benefit. The trial would have prospectively determined the incidence of cardiovascular events, whose possible association with coxib treatment had not been anticipated in the early and pivotal trials of these drugs.
Unfortunately, such a trial was never done. The FDA has the authority to mandate that a trial be conducted, but it never took the initiative. Instead of conducting such a trial at any point — and especially after the FDA advisory committee meeting in 2001 — Merck issued a relentless series of publications, beginning with a press release on May 22, 2001, entitled “Merck Reconfirms Favorable Cardiovascular Safety of Vioxx” and complemented by numerous papers in peer-reviewed medical literature by Merck employees and their consultants. The company sponsored countless continuing medical “education” symposiums at national meetings in an effort to debunk the concern about adverse cardiovascular effects. The message that was duly reinforced was that rofecoxib had no cardiovascular toxicity: rather, naproxen was cardioprotective. Only by happenstance, in a trial involving 2600 patients with colon polyps who could not have been enrolled if they had had any cardiovascular disease, was it discovered that 3.5 percent of the patients assigned to rofecoxib had myocardial infarction or stroke, as compared with 1.9 percent of the patients assigned to placebo (P<0.001), necessitating premature cessation of the trial and the decision to discontinue treatment with rofecoxib.
Over the course of the five-and-a-half-year saga, many epidemiologic studies confirmed and amplified the concern about the risk of myocardial infarction and serious cardiovascular events associated with rofecoxib.3 These studies considered large populations, up to 1.4 million patients, tracking the use of various nonsteroidal antiinflammatory medications or coxibs to determine the risk of adverse events. Each time a study was presented or published, there was a predictable and repetitive response from Merck, which claimed that the study was flawed and that only randomized, controlled trials were suitable for determining whether there was any risk. But if Merck would not initiate an appropriate trial and the FDA did not ask them to do so, how would the truth ever be known?
Meanwhile, Merck was spending more than $100 million per year in direct-to-consumer advertising — another activity regulated by the FDA and a critical mechanism in building the “blockbuster” status of a drug with annual sales of more than $1 billion. For the past few years, every month has seen more than 10 million prescriptions for rofecoxib written in the United States alone. At any point, the FDA could have stopped Merck from using direct-to-consumer advertising, especially given the background concern that the cardiovascular toxicity was real and was receiving considerable confirmation in multiple studies conducted by investigators who were independent of Merck. The only significant action taken by the FDA occurred on April 11, 2002, when the agency instructed Merck to include certain precautions about cardiovascular risks in its package insert. The FDA also sponsored one of the large epidemiologic studies performed in a cohort of Kaiser Permanente patients.
Considering the tens of millions of patients who were taking rofecoxib, we are dealing with an enormous public health issue. Even a fraction of a percent excess in the rate of serious cardiovascular events would translate into thousands of affected people. Given the finding in the colon-polyp trial in low-risk patients without known cardiovascular disease — an excess of 16 myocardial infarctions or strokes per 1000 patients — there may be tens of thousands of patients who have had major adverse events attributable to rofecoxib (see Figure
Risk of Myocardial Infarction (MI) or Stroke Associated with Rofecoxib Use.).I believe that there should be a full Congressional review of this case. The senior executives at Merck and the leadership at the FDA share responsibility for not having taken appropriate action and not recognizing that they are accountable for the public health. Sadly, it is clear to me that Merck's commercial interest in rofecoxib sales exceeded its concern about the drug's potential cardiovascular toxicity. Had the company not valued sales over safety, a suitable trial could have been initiated rapidly at a fraction of the cost of Merck's direct-to-consumer advertising campaign. Despite the best efforts of many investigators to conduct and publish meaningful independent research concerning the cardiovascular toxicity of rofecoxib, only the FDA is given the authority to act. In my view, the FDA's passive position of waiting for data to accrue is not acceptable, given the strong signals that there was a problem and the vast number of patients who were being exposed. Furthermore, the tradeoff here involved a drug for symptoms of arthritis, for which many alternative medications are available, in the context of serious, life-threatening cardiovascular complications. Certainly there are many facts that we are not privy to, such as the direct communication between the FDA and Merck, but all the facts can and should be scrutinized closely in a Congressional review in order to avert such a catastrophe in the future.
Source Information
From the Cleveland Clinic Foundation, Cleveland.
- References
References
1
Bombardier C ,Laine L ,Reicin A , et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528
Full Text | Web of Science | Medline2
Mukherjee DM ,Nissen SE ,Topol EJ . Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959
CrossRef | Web of Science | Medline3
Topol EJ ,Falk GW . A coxib a day won't keep the doctor away. Lancet 2004;364:639-640
CrossRef | Web of Science | Medline
- Citing Articles (163)
Citing Articles
1
Adam G. Dunn, Blanca Gallego, Enrico Coiera. (2012) Industry influenced evidence production in collaborative research communities: A network analysis. Journal of Clinical Epidemiology
CrossRef2
Francesca Pistollato, Susanne Bremer-Hoffmann, Lyn Healy, Lesley Young, Glyn Stacey. (2012) Standardization of pluripotent stem cell cultures for toxicity testing. Expert Opinion on Drug Metabolism & Toxicology239-257
CrossRef3
Mei-ling Liu, Yan-qiao Zhang, Yi-na Zhang, Li-chun Pei, Xin Liu. (2011) Prostaglandin E2 receptor 1 activity regulates cell survival following hypoxia in cultured rat cortical neurons. Neuroscience Letters
CrossRef4
Amy Brock, Hui-Tong Goh, Binxia Yang, Yu Lu, Hu Li, Yuin-Han Loh. (2011) Cellular Reprogramming: A New Technology Frontier in Pharmaceutical Research. Pharmaceutical Research
CrossRef5
Jonathan A.L. Gelfond, Elizabeth Heitman, Brad H. Pollock, Craig M. Klugman. (2011) Principles for the ethical analysis of clinical and translational research. Statistics in Medicine 30:23, 2785-2792
CrossRef6
Peter C Gøtzsche, David Tovey. 2011. We need access to all data from all clinical trials. .
CrossRef7
Veronica Scurti, Marilena Romero, Gianni Tognoni. (2011) A plea for a more epidemiological and patient-oriented pharmacovigilance. European Journal of Clinical Pharmacology
CrossRef8
JANET HOEK, PHILIP GENDALL, LARA RAPSON, JORDAN LOUVIERE. (2011) Information Accessibility and Consumers' Knowledge of Prescription Drug Benefits and Risks. Journal of Consumer Affairs 45:2, 248-274
CrossRef9
Lun Yang, Ke-Jian Wang, Li-Shan Wang, Anil G. Jegga, Sheng-Ying Qin, Guang He, Jian Chen, Yue Xiao, Lin He. (2011) Chemical-protein interactome and its application in off-target identification. Interdisciplinary Sciences: Computational Life Sciences 3:1, 22-30
CrossRef10
Mayer Brezis, William H. Wiist. (2011) Vulnerability of Health to Market Forces. Medical Care 49:3, 232-239
CrossRef11
H. Brody, D. W. Light. (2011) The Inverse Benefit Law: How Drug Marketing Undermines Patient Safety and Public Health. American Journal of Public Health 101:3, 399-404
CrossRef12
Anna M. Wobus, Peter Löser. (2011) Present state and future perspectives of using pluripotent stem cells in toxicology research. Archives of Toxicology 85:2, 79-117
CrossRef13
Aurélie Roux, Dominique Lison, Christophe Junot, Jean-François Heilier. (2011) Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: A review. Clinical Biochemistry 44:1, 119-135
CrossRef14
Peter C Gotzsche. (2011) Why we need easy access to all data from all clinical trials and how to accomplish it. Trials 12:1, 249
CrossRef15
Subhalakshmi Ghosh, Madhushree Das Sarma, Amarendra Patra, Banasri Hazra. (2010) Anti-inflammatory and anticancer compounds isolated from Ventilago madraspatana Gaertn., Rubia cordifolia Linn. and Lantana camara Linn.. Journal of Pharmacy and Pharmacology 62:9, 1158-1166
CrossRef16
S.J. Genuis, D. Birkholz, M. Ralitsch, N. Thibault. (2010) Human detoxification of perfluorinated compounds. Public Health 124:7, 367-375
CrossRef17
Anders W. Jørgensen, Karsten Juhl Jørgensen, Peter C. Gøtzsche. (2010) Unbalanced reporting of benefits and harms in abstracts on rofecoxib. European Journal of Clinical Pharmacology 66:4, 341-347
CrossRef18
G. Caleb Alexander. (2010) Clinical Prescribing (and Off-Label Use) in a Second-Best World. Medical Care 48:4, 285-287
CrossRef19
W. DAVID BRADFORD, ANDREW N. KLEIT, PAUL J. NIETERT, STEVEN ORNSTEIN. (2010) THE EFFECT OF DIRECT TO CONSUMER TELEVISION ADVERTISING ON THE TIMING OF TREATMENT. Economic Inquiry 48:2, 306-322
CrossRef20
Sandra Niro, Olivier Hennebert, Robert Morfin. (2010) A native steroid hormone derivative triggers the resolution of inflammation. Hormone Molecular Biology and Clinical Investigation 1:1, 11-19
CrossRef21
Barbara Mintzes, Dee Mangin. (2009) Opinion: Direct-to-consumer advertising of prescription medicines: a counter argument. Future Medicinal Chemistry 1:9, 1555-1560
CrossRef22
K. D. Rainsford. (2009) Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 17:6, 275-342
CrossRef23
Martha Myslinski Tipton, Sundar G Bharadwaj, Diana C Robertson. (2009) Regulatory Exposure of Deceptive Marketing and Its Impact on Firm Value. Journal of Marketing 73:6, 227-243
CrossRef24
Benedict W. Wheeler, Chris Metcalfe, David Gunnell, Peter Stephens, Richard M. Martin. (2009) Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study. British Journal of Clinical Pharmacology 68:5, 752-764
CrossRef25
James M. Ritter, Idris Harding, John B. Warren. (2009) Precaution, cyclooxygenase inhibition, and cardiovascular risk. Trends in Pharmacological Sciences 30:10, 503-508
CrossRef26
Irfan A. Dhalla, Sarah Garner, Kalipso Chalkidou, Peter Littlejohns. (2009) Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research. International Journal of Technology Assessment in Health Care 25:03, 272
CrossRef27
Yama A. Abassi, Biao Xi, Wenfu Zhang, Peifang Ye, Shelli L. Kirstein, Michelle R. Gaylord, Stuart C. Feinstein, Xiaobo Wang, Xiao Xu. (2009) Kinetic Cell-Based Morphological Screening: Prediction of Mechanism of Compound Action and Off-Target Effects. Chemistry & Biology 16:7, 712-723
CrossRef28
Linsey McGoey. (2009) Pharmaceutical Controversies and the Performative Value of Uncertainty. Science as Culture 18:2, 151-164
CrossRef29
Rasmus T. Hoeg, Jennifer A. Lee, Michelle A. Mathiason, Kristina Rokkones, Stephanie L. Serck, Kaye L. Crampton, Ann E. Emmel, Eileen A. Severson, Ronald S. Go. (2009) Publication Outcomes of Phase II Oncology Clinical Trials. American Journal of Clinical Oncology 32:3, 253-257
CrossRef30
Joel Katz, Ze’ev Seltzer. (2009) Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert Review of Neurotherapeutics 9:5, 723-744
CrossRef31
Christine Y. Lu. (2009) Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases. Clinical Rheumatology 28:4, 371-377
CrossRef32
Giovanni Polimeni, Alessandra Russo, Maria Antonietta Catania, Andrea Aiello, Alessandro Oteri, Gianluca Trifirò, Gioacchino Calapai, Lidia Sautebin, Massimo Iacobelli, Achille P. Caputi. (2009) Drug Safety Information Through the Internet. Drug Safety 32:3, 245-253
CrossRef33
Dan M. Roden. 2009. Toxicology and Genetics of Adverse Drug Events. , 339-344.
CrossRef34
Alan Kivitz, Michael Fairfax, Eric A. Sheldon, Qinfang Xiang, Beverly A. Jones, Arnold R. Gammaitoni, Errol M. Gould. (2008) Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: Post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults. Clinical Therapeutics 30:12, 2366-2377
CrossRef35
Shawn Hoon, Robert P. St.Onge, Guri Giaever, Corey Nislow. (2008) Yeast chemical genomics and drug discovery: an update. Trends in Pharmacological Sciences 29:10, 499-504
CrossRef36
Carolyn B. Sufrin, Joseph S. Ross. (2008) Pharmaceutical Industry Marketing: Understanding Its Impact on Women’s Health. Obstetrical & Gynecological Survey 63:9, 585-596
CrossRef37
Peter Ian Pillans. (2008) Clinical perspectives in drug safety and adverse drug reactions. Expert Review of Clinical Pharmacology 1:5, 695-705
CrossRef38
A. Sommet, S. Grolleau, H. Bagheri, M. Lapeyre-Mestre, J. L. Montastruc, . (2008) Was the thrombotic risk of rofecoxib predictible from the French Pharmacovigilance Database before 30 September 2004?. European Journal of Clinical Pharmacology 64:8, 829-834
CrossRef39
J T Cross, E M Poole, C M Ulrich. (2008) A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. The Pharmacogenomics Journal 8:4, 237-247
CrossRef40
Gábor Lakatos, László Herszényi, Zsolt Tulassay. (2008) A COX-2-gátlók biztonságossága. Orvosi Hetilap 149:33, 1539-1547
CrossRef41
L. Härmark, A. C. Grootheest. (2008) Pharmacovigilance: methods, recent developments and future perspectives. European Journal of Clinical Pharmacology 64:8, 743-752
CrossRef42
Cameron Rhudy. (2008) How Congress May Have Failed Consumers with the Food and Drug Administration Amendments Act of 2007. Biotechnology Law Report 27:2, 99-108
CrossRef43
Carpenter, Daniel, Zucker, Evan James, Avorn, Jerry, . (2008) Drug-Review Deadlines and Safety Problems. New England Journal of Medicine 358:13, 1354-1361
Full Text44
N. Pearce, J. Douwes. (2008) Response: Time for species--course epidemiology?. International Journal of Epidemiology 38:2, 403-410
CrossRef45
Debabrata Mukherjee. (2008) Nonsteroidal Anti-Inflammatory Drugs and the Heart: What Is the Danger?. Congestive Heart Failure 14:2, 75-82
CrossRef46
James M. O’Brien, Scott K. Aberegg. (2008) Our failure to report failure*. Critical Care Medicine 36:3, 1002-1003
CrossRef47
Janet Hoek. (2008) Ethical and practical implications of pharmaceutical direct-to-consumer advertising. International Journal of Nonprofit and Voluntary Sector Marketing 13:1, 73-87
CrossRef48
Turner, Erick H., Matthews, Annette M., Linardatos, Eftihia, Tell, Robert A., Rosenthal, Robert, . (2008) Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. New England Journal of Medicine 358:3, 252-260
Full Text49
Russell Jaffe, Robert A. Nash, Richard Ash, Norm Schwartz, Robert Corish, Tammy Born, James P. Carter, Harold Lazarus. (2008) Role of transparency in managing outcome successes: Causes and end use/least cost as decision guides. Journal of Management Development 27:10, 1086-1114
CrossRef50
Nicholas Freudenberg, Sandro Galea. (2008) The Impact of Corporate Practices on Health: Implications for Health Policy. Journal of Public Health Policy 29:1, 86-104
CrossRef51
Aruna V Krishnan, Jacqueline Moreno, Larisa Nonn, Srilatha Swami, Donna M Peehl, David Feldman. (2007) Calcitriol as a Chemopreventive and Therapeutic Agent in Prostate Cancer: Role of Anti-Inflammatory Activity. Journal of Bone and Mineral Research 22:S2, V74-V80
CrossRef52
Leon Flicker, Osvaldo P. Almeida. (2007) Commentary. International Psychogeriatrics 19:06,
CrossRef53
Donald R. Miller, D. John Doyle. (2007) Understanding the open access data movement. Canadian Journal of Anesthesia/Journal canadien d'anesthésie 54:11, 949-950
CrossRef54
V. A. Tverdislov, L. V. Yakovenko, A. A. Zhavoronkov. (2007) Chirality as a problem of biochemical physics. Russian Journal of General Chemistry 77:11, 1994-2005
CrossRef55
Adam Institoris, Eszter Farkas, Sandor Berczi, Zoltan Sule, Ferenc Bari. (2007) Effects of cyclooxygenase (COX) inhibition on memory impairment and hippocampal damage in the early period of cerebral hypoperfusion in rats. European Journal of Pharmacology 574:1, 29-38
CrossRef56
Mary Teeling, Humphrey O'Connor, John Feely, Kathleen Bennett. (2007) What therapies have replaced rofecoxib in Ireland?. British Journal of Clinical Pharmacology 64:4, 536-541
CrossRef57
Tracy A. Lieu, Martin Kulldorff, Robert L. Davis, Edwin M. Lewis, Eric Weintraub, Katherine Yih, Ruihua Yin, Jeffrey S. Brown, Richard Platt. (2007) Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events. Medical Care 45:Suppl 2, S89-S95
CrossRef58
K GROOM. (2007) Pharmacological prevention of prematurity. Best Practice & Research Clinical Obstetrics & Gynaecology 21:5, 843-856
CrossRef59
Kathy Archibald, Margaret Clotworthy. (2007) Comment on ‘The ethics of animal research’ by Festing & Wilkinson. EMBO reports 8:9, 794-796
CrossRef60
Deanna M. Minich, Jeffrey S. Bland, Jeffrey Katke, Gary Darland, Amy Hall, Robert H. Lerman, Joseph Lamb, Brian Carroll, Matthew Tripp. (2007) Clinical safety and efficacy of NG440: a novel combination of rho iso-alpha acids from hops, rosemary, and oleanolic acid for inflammatory conditionsThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products.. Canadian Journal of Physiology and Pharmacology 85:9, 872-883
CrossRef61
M. J. James, R. J. Cook-Johnson, L. G. Cleland. (2007) Selective COX-2 Inhibitors, Eicosanoid Synthesis and Clinical Outcomes: A Case Study of System Failure. Lipids 42:9, 779-785
CrossRef62
(2007) A National Survey of Physician–Industry Relationships. New England Journal of Medicine 357:5, 507-508
Full Text63
Brendan J. Kelley, Ronald C. Petersen. (2007) Alzheimer's Disease and Mild Cognitive Impairment. Neurologic Clinics 25:3, 577-609
CrossRef64
David Feldman, Aruna Krishnan, Jacqueline Moreno, Srilatha Swami, Donna M. Peehl, Sandy Srinivas. (2007) Vitamin D Inhibition of the Prostaglandin Pathway as Therapy for Prostate Cancer. Nutrition Reviews 65, S113-S115
CrossRef65
R A Madan, Q Xia, V T Chang, R G Oriscello, B Kasimis. (2007) A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib. Expert Opinion on Pharmacotherapy 8:10, 1425-1431
CrossRef66
Chrysostomos P. Panayiotopoulos. (2007) Evidence-based Epileptology, Randomized Controlled Trials, and SANAD: A Critical Clinical View. Epilepsia 48:7, 1268-1274
CrossRef67
Li-Chia Chen, Darren M Ashcroft. (2007) Risk of myocardial infarction associated with selective COX-2 inhibitors: Meta-analysis of randomised controlled trials. Pharmacoepidemiology and Drug Safety 16:7, 762-772
CrossRef68
Vincent Lo Re, Brian L. Strom. (2007) The role of academia and the research community in assisting the food and drug administration to ensure U.S. drug safety. Pharmacoepidemiology and Drug Safety 16:7, 818-825
CrossRef69
James M. O???Brien. (2007) Recombinant human activated protein C sentenced to the death of a thousand cuts?*. Critical Care Medicine 35:6, 1609-1610
CrossRef70
A M Feldman, W J Koch, T L Force. (2007) Developing Strategies to Link Basic Cardiovascular Sciences with Clinical Drug Development: Another Opportunity for Translational Sciences. Clinical Pharmacology & Therapeutics 81:6, 887-892
CrossRef71
Martin Friedrich. (2007) Evidenz- und konsensusbasierte österreichische Leitlinien für das Management akuter und chronischer unspezifischer Kreuzschmerzen. Wiener klinische Wochenschrift 119:5-6, 189-197
CrossRef72
Aruna V. Krishnan, Jacqueline Moreno, Larisa Nonn, Peter Malloy, Srilatha Swami, Lihong Peng, Donna M. Peehl, David Feldman. (2007) Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 103:3-5, 694-702
CrossRef73
N.J. WOOD, N.A. QUINTON, S. BURDALL, E. SHERIDAN, S.R. DUFFY. (2007) Exploring the potential chemopreventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer?like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression. International Journal of Gynecological Cancer 17:2, 447-454
CrossRef74
Robert Boruch. (2007) The null hypothesis is not called that for nothing: statistical tests in randomized trials. Journal of Experimental Criminology 3:1, 1-20
CrossRef75
David Armstrong. (2007) Professionalism, Indeterminacy and the EBM Project. BioSocieties 2:1, 73-84
CrossRef76
Alexander Kunz, Josef Anrather, Ping Zhou, Marcello Orio, Costantino Iadecola. (2007) Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species. Journal of Cerebral Blood Flow & Metabolism 27:3, 545-551
CrossRef77
Young Ho Lee, Jong Dae Ji, Gwan Gyu Song. (2007) Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. Rheumatology International 27:5, 477-482
CrossRef78
Robert M. Califf, . (2007) Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. Pharmacoepidemiology and Drug Safety 16:1, 5-16
CrossRef79
Wally R. Smith. (2007) Pseudoevidence-based medicine: what it is, and what to do about it. Clinical Governance: An International Journal 12:1, 42-52
CrossRef80
Russell Jaffe, Robert A. Nash, Richard Ash, Norm Schwartz, Robert Corish, Tammy Born, Harold Lazarus. (2007) An equation of health: Role of transparency and opacity in developing healthcare efficacy measures and metrics. Journal of Management Development 26:5, 441-458
CrossRef81
Ignatius Gerardo E. Zarraga, Ernst R. Schwarz. (2007) Coxibs and Heart Disease. Journal of the American College of Cardiology 49:1, 1-14
CrossRef82
Jen-pei Liu. (2007) Rethinking Statistical Approaches to Evaluating Drug Safety. Yonsei Medical Journal 48:6, 895
CrossRef83
Sumera Ilyas, Cathrine J. DeMars, Navtej S. Buttar. (2007) Chemoprevention in Barrett’s Esophagus. Journal of Gastrointestinal Cancer 38:1, 1-9
CrossRef84
Justin Biddle. (2007) Lessons from the Vioxx Debacle: What the Privatization of Science Can Teach Us About Social Epistemology. Social Epistemology 21:1, 21-39
CrossRef85
Wasim Haque, Jawed Fareed, William H. Wehrmacher, Harry L. Messmore. (2006) The classical vs nonclassical NSAIDs. Comprehensive Therapy 32:4, 261-266
CrossRef86
Gustavo Batista Menezes, Webster Glayser Pimenta Reis, Júlia Maria Moreira Santos, Igor Dimitri Gama Duarte, Janetti Nogueira Francischi. (2006) Inhibition of Prostaglandin % MathType!Translator!2!1!AMS LaTeX.tdl!TeX -- AMS-LaTeX!% MathType!MTEF!2!1!+-% feaaeaart1ev0aaatCvAUfeBSjuyZL2yd9gzLbvyNv2CaerbbjxAHX% garmWu51MyVXgatuuDJXwAK1uy0HwmaeHbfv3ySLgzG0uy0Hgip5wz% aebbnrfifHhDYfgasaacH8qrps0lbbf9q8WrFfeuY-Hhbbf9v8qqaq% Fr0xc9pk0xbba9q8WqFfea0-yr0RYxir-Jbba9q8aq0-yq-He9q8qq% Q8frFve9Fve9Ff0dmeaabaqaciGacaGaaeqabaWaaeWaeaaakeaajy% aGcaqGgbGcdaWgaaWcbaqcfaOaaeOmaSGaeqySdegabeaaaaa!3C0B! $${\text{F}}_{{{\text{2}}\alpha }} $$ by Selective Cyclooxygenase 2 Inhibitors Accounts for Reduced Rat Leukocyte Migration. Inflammation 29:4-6, 163-169
CrossRef87
Fernando Alfonso, Javier Segovia, Magda Heras, Javier Bermejo. (2006) Publicación de ensayos clínicos en revistas científicas: consideraciones editoriales. Revista Española de Cardiología 59:11, 1206-1214
CrossRef88
Sandra J. Hewett, Stanley C. Bell, James A. Hewett. (2006) Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system. Pharmacology & Therapeutics 112:2, 335-357
CrossRef89
Weng-Foung Huang, Fei-Yuan Hsiao, Yu-Wen Wen, Y-Wen Tsai. (2006) Cardiovascular events associated with the use of four nonselective NSAIDs (Etodolac, Nabumetone, Ibuprofen, or Naproxen) Versus a Cyclooxygenase-2 Inhibitor (Celecoxib): A population-based analysis in taiwanese adults. Clinical Therapeutics 28:11, 1827-1836
CrossRef90
Japie A Louw. (2006) Peptic ulcer disease. Current Opinion in Gastroenterology 22:6, 607-611
CrossRef91
Alex Cahana, Alexandre Mauron. (2006) The story of Vioxx—no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry. Journal of Anesthesia 20:4, 348-351
CrossRef92
Subhalakshmi Basu, Banasri Hazra. (2006) Evaluation of nitric oxide scavenging activity,In Vitro andEx Vivo, of selected medicinal plants traditionally used in inflammatory diseases. Phytotherapy Research 20:10, 896-900
CrossRef93
Theoharis C. Theoharides. 2006. Synovial Mast Cells in Inflammatory Arthritis. .
CrossRef94
C. A Bond, Cynthia L Raehl. (2006) Clinical Pharmacy Services, Pharmacy Staffing, and Adverse Drug Reactions in United States Hospitals. Pharmacotherapy 26:6, 735-747
CrossRef95
C. J. Hawkey, G. M. Hawkey, S. Everitt, M. M. Skelly, W. A. Stack, D. Gray. (2006) Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology 61:6, 730-737
CrossRef96
Noel G. Carlson, Kenneth E. Hill, Ikuo Tsunoda, Robert S. Fujinami, John W. Rose. (2006) The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: Implications for multiple sclerosis. Journal of Neuroimmunology 174:1-2, 21-31
CrossRef97
C. A Bond, Cynthia L Raehl. (2006) Adverse Drug Reactions in United States Hospitals. Pharmacotherapy 26:5, 601-608
CrossRef98
Richard L. Popp, Beverly H. Lorell, Gregg W. Stone, Warren Laskey, John J. Smith, Aaron V. Kaplan. (2006) An Outline for Public Registration of Clinical Trials Evaluating Medical Devices. Journal of the American College of Cardiology 47:8, 1518-1521
CrossRef99
Beatriz Pérez Zafrilla, Javier García del Pozo, Antonio Aguilar Ros, Francisco J. de Abajo. (2006) Calidad de los estudios postautorización de tipo observacional registrados en España antes de su regulación. Medicina Clínica 126:16, 607-610
CrossRef100
Christopher M. Overall, Oded Kleifeld. (2006) Tumour microenvironment — Opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Reviews Cancer 6:3, 227-239
CrossRef101
Michael A. Steinman, Kenneth R. McQuaid, Kenneth E. Covinsky. (2006) Age and Rising Rates of Cyclooxygenase-2 Inhibitor Use. Results from a National Survey. Journal of General Internal Medicine 21:3, 245-250
CrossRef102
Takayuki Kawano, Josef Anrather, Ping Zhou, Laibaik Park, Gang Wang, Kelly A Frys, Alexander Kunz, Sunghee Cho, Marcello Orio, Costantino Iadecola. (2006) Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nature Medicine 12:2, 225-229
CrossRef103
Christopher J Hawkey, Paul J Fortun. (2006) Cyclooxygenase-2 inhibitors. Current Opinion in Internal Medicine 5:1, 106-110
CrossRef104
Ray, Wayne A., Stein, C. Michael, . (2006) Reform of Drug Regulation — Beyond an Independent Drug-Safety Board. New England Journal of Medicine 354:2, 194-201
Full Text105
Maurits W. Tulder, Bart Koes, Antti Malmivaara. (2006) Outcome of non-invasive treatment modalities on back pain: an evidence-based review. European Spine Journal 15:S1, S64-S81
CrossRef106
T. Horiguchi, J.A. Snipes, B. Kis, K. Shimizu, D.W. Busija. (2006) Cyclooxygenase-2 mediates the development of cortical spreading depression-induced tolerance to transient focal cerebral ischemia in rats. Neuroscience 140:2, 723-730
CrossRef107
Jane A. Mitchell, Timothy D. Warner. (2006) COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nature Reviews Drug Discovery 5:1, 75-86
CrossRef108
Justin Stebbing, Mark Bower. (2006) Comparative pharmacogenomics of antiretroviral and cytotoxic treatments. The Lancet Oncology 7:1, 61-68
CrossRef109
Peter J Embi, Prasad Acharya, Mark McCuistion, Charles P Kishman, Doris Haag, Stephen Marine. (2006) Responding Rapidly to FDA Drug Withdrawals: Design and Application of a New Approach for a Consumer Health Website. Journal of Medical Internet Research 8:3, e16
CrossRef110
Weng-Foung Huang, Fei-Yuan Hsiao, Yi-Wen Tsai, Yu-Wen Wen, Yaw-Tang Shih. (2006) Cardiovascular Events Associated with Long-Term Use of Celecoxib, Rofecoxib and Meloxicam in Taiwan. Drug Safety 29:3, 261-272
CrossRef111
Richard L. Kravitz. (2006) Author's Reply. PLoS Medicine 3:6, e285
CrossRef112
Elizabeth A. Almasi, Randall S. Stafford, Richard L. Kravitz, Peter R. Mansfield. (2006) What Are the Public Health Effects of Direct-to-Consumer Drug Advertising?. PLoS Medicine 3:3, e145
CrossRef113
Stephen J. Genuis. (2006) Diagnosis: contemporary medical hubris; Rx: a tincture of humility. Journal of Evaluation in Clinical Practice 12:1, 24-30
CrossRef114
Bruce D. Levy. (2005) Eicosanoids in scleroderma: Lung disease hangs in the balance. Arthritis & Rheumatism 52:12, 3693-3697
CrossRef115
Carles Vallvé, Maite Artés, Erik Cobo. (2005) Estudios de intervención no aleatorizados (TREND). Medicina Clínica 125, 38-42
CrossRef116
Robert J. Kaplan. (2005) Current Status of NonsteroidalAnti-Inflammatory Drugsin Physiatry. American Journal of Physical Medicine & Rehabilitation 84:11, 885-894
CrossRef117
James M Brophy. (2005) Celecoxib and cardiovascular risks. Expert Opinion on Drug Safety 4:6, 1005-1015
CrossRef118
Christianne L. Roumie, Patrick G. Arbogast, Edward F. Mitchel, Marie R. Griffin. (2005) Prescriptions for Chronic High-Dose Cyclooxygenase-2 Inhibitors are Often Inappropriate and Potentially Dangerous. Journal of General Internal Medicine 20:10, 879-883
CrossRef119
A. Brack, H. L. Rittner, M. Schäfer. (2005) Kritische Neubewertung von Zyklooxygenase-2-Inhibitoren in der perioperativen Schmerztherapie. Der Anaesthesist 54:10, 1032-1038
CrossRef120
Franklin G. Miller, Howard Brody. (2005) Viewpoint:. Academic Medicine 80:10, 899-904
CrossRef121
Paul J. Limburg, Wenqiang Wei, Dennis J. Ahnen, Youlin Qiao, Ernest T. Hawk, Guoqing Wang, Carol A. Giffen, Guiqi Wang, Mark J. Roth, Ning Lu, Edward L. Korn, Yurong Ma, Kathleen L. Caldwell, Zheiwei Dong, Philip R. Taylor, Sanford M. Dawsey. (2005) Randomized, Placebo-Controlled, Esophageal Squamous Cell Cancer Chemoprevention Trial of Selenomethionine and Celecoxib. Gastroenterology 129:3, 863-873
CrossRef122
Stefan R. Florentinus, Eibert R. Heerdink, Antonius de Boer, Liset van Dijk, Hubert G.M. Leufkens. (2005) The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiology and Drug Safety 14:9, 669-669
CrossRef123
John H. Stone, Michael D. Lockshin, Patricia P. Katz, Edward H. Yelin. (2005) New journal policy regarding registration of clinical trials. Arthritis & Rheumatism 53:4, 484-487
CrossRef124
John H. Stone, Michael D. Lockshin, Patricia P. Katz, Edward H. Yelin. (2005) New journal policy regarding registration of clinical trials. Arthritis & Rheumatism 52:8, 2243-2247
CrossRef125
M. Atik. (2005) A Proposal for Evaluation of Platelet Aggregation and Adhesiveness for Clinical Trials with Cyclooxygenase Inhibitors and Nonsteroidal Antiinflammatory Drugs. Journal of the American College of Surgeons 201:2, 263-264
CrossRef126
D. PEREG, M. LISHNER. (2005) Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. Journal of Internal Medicine 258:2, 115-123
CrossRef127
Matthew Foster, Ralph Kendall, Mary Todd. (2005) COX-2 Inhibitor Safety in the Workers?? Compensation Market. Lippincott's Case Management 10:4, 217???220
CrossRef128
Matthew Wagner, James Loos, Nicole Weksler, Marin Gantner, Christopher L. Corless, John M. Barry, Tomasz M. Beer, Mark Garzotto. (2005) Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochemical and Biophysical Research Communications 332:3, 800-807
CrossRef129
Bernard Hirschel. (2005) Effect of rimonabant on weight reduction and cardiovascular risk. The Lancet 366:9483, 369
CrossRef130
Alasdair Breckenridge, Kent Woods, June Raine. (2005) Essay: Monitoring the safety of licensed medicines. Nature Reviews Drug Discovery 4:7, 541-543
CrossRef131
Stefan R. Florentinus, Eibert R. Heerdink, Antonius de Boer, Liset van Dijk, Hubert G. M. Leufkens. (2005) The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiology and Drug Safety 14:7, 437-441
CrossRef132
Sharon J. Gardiner, Evan J. Begg, Mei Zhang, Ruth C. E. Hughes. (2005) Transfer of rofecoxib into human milk. European Journal of Clinical Pharmacology 61:5-6, 405-408
CrossRef133
R. De Caterina, M. Massaro. (2005) Omega-3 Fatty Acids and the Regulation of Expression of Endothelial Pro-Atherogenic and Pro-Inflammatory Genes. Journal of Membrane Biology 206:2, 103-116
CrossRef134
Schuyler W. Henderson, Andrés Martin. (2005) The Truth About Drug Companies: How They Deceive Us and What to Do About It.. Journal of the American Academy of Child & Adolescent Psychiatry 44:6, 601-603
CrossRef135
Mello, Michelle M., Clarridge, Brian R., Studdert, David M., . (2005) Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry. New England Journal of Medicine 352:21, 2202-2210
Full Text136
Masanobu Oshima, Hiroko Oshima, Makoto M. Taketo. (2005) Hypergravity induces expression of cyclooxygenase-2 in the heart vessels. Biochemical and Biophysical Research Communications 330:3, 928-933
CrossRef137
Joan C Bevan. (2005) Guidelines on the ethics of clinical research in anaesthesia. Current Opinion in Anaesthesiology 18:2, 189-194
CrossRef138
Heike A. Wieland, Martin Michaelis, Bernhard J. Kirschbaum, Karl A. Rudolphi. (2005) Osteoarthritis — an untreatable disease?. Nature Reviews Drug Discovery 4:4, 331-344
CrossRef139
Eisenberg, Rebecca S., . (2005) Learning the Value of Drugs — Is Rofecoxib a Regulatory Success Story?. New England Journal of Medicine 352:13, 1285-1287
Full Text140
Solomon, Scott D., McMurray, John J.V., Pfeffer, Marc A., Wittes, Janet, Fowler, Robert, Finn, Peter, Anderson, William F., Zauber, Ann, Hawk, Ernest, Bertagnolli, Monica, . (2005) Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. New England Journal of Medicine 352:11, 1071-1080
Full Text141
Mark Greener. (2005) Drug safety on trial. EMBO reports 6:3, 202-204
CrossRef142
Cesare Gridelli, Antonio Rossi, Paolo Maione. (2005) Treatment of non-small cell lung cancer and targeted therapies: where are we?. Current Opinion in Oncology 17:2, 114-117
CrossRef143
David J. Triggle. (2005) Vaccines, Viagra, and Vioxx: medicines, markets, and money—when life-saving meets life-style. Drug Development Research 64:2, 90-98
CrossRef144
Ronald Esser, Carol Berry, Zhengming Du, Janet Dawson, Alyson Fox, Roger A Fujimoto, William Haston, Earl F Kimble, Julie Koehler, Jane Peppard, Elizabeth Quadros, Joseph Quintavalla, Karen Toscano, Laszlo Urban, John Duzer, Xiaoli Zhang, Siyuan Zhou, Paul J Marshall. (2005) Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. British Journal of Pharmacology 144:4, 538-550
CrossRef145
A. Li Wan Po. (2005) Drug evaluation, drug development and pharmacogenetics: celebrating 30 years of progress. Journal of Clinical Pharmacy and Therapeutics 30:1, 1-4
CrossRef146
David J Graham, David Campen, Rita Hui, Michele Spence, Craig Cheetham, Gerald Levy, Stanford Shoor, Wayne A Ray. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. The Lancet 365:9458, 475-481
CrossRef147
Leleti Rajender Reddy, E.J. Corey. (2005) Facile air oxidation of the conjugate base of rofecoxib (Vioxx™), a possible contributor to chronic human toxicity. Tetrahedron Letters 46:6, 927-929
CrossRef148
Xavier Carn
, N
CrossRef149
Simon Frantz. (2005) Dangerous drugs?. news@nature
CrossRef150
John P. A. Ioannidis. (2005) Why Most Published Research Findings Are False. PLoS Medicine 2:8, e124
CrossRef151
Torbj??rn Callr??us. (2005) The Precautionary Principle and Pharmaceutical Risk Management. Drug Safety 28:6, 465-471
CrossRef152
Frank T. Ruschitzka. (2005) Clinical Trials Report. Current Hypertension Reports 7:1, 41-43
CrossRef153
Florian Krötz, Thomas M. Schiele, Volker Klauss, Hae-Young Sohn. (2005) Selective COX-2 Inhibitors and Risk of Myocardial Infarction. Journal of Vascular Research 42:4, 312-324
CrossRef154
Andreas Stang, Hans-Werner Hense, Karl-Heinz Jöckel, Erick H. Turner, Martin R. Tramèr. (2005) Is It Always Unethical to Use a Placebo in a Clinical Trial?. PLoS Medicine 2:3, e72
CrossRef155
M. Labetoulle. (2005) Le retrait du Vioxx™ : des leçons pour tous. Journal Français d'Ophtalmologie 28:1, 126-127
CrossRef156
Thomas R McLean. (2005) Discontinuation of Vioxx. The Lancet 365:9453, 25
CrossRef157
Bernard Bannwarth. (2005) Do Selective Cyclo-Oxygenase-2 Inhibitors Have a Future?. Drug Safety 28:3, 183-189
CrossRef158
Ida Sim, Don E. Detmer. (2005) Beyond Trial Registration: A Global Trial Bank for Clinical Trial Reporting. PLoS Medicine 2:11, e365
CrossRef159
(2004) Rofecoxib, Merck, and the FDA. New England Journal of Medicine 351:27, 2875-2878
Full Text160
Bèr Pleumeekers. (2004) COX-2-remmers: in dubio abstine. Huisarts en Wetenschap 47:13, 15-16
CrossRef161
Trudo Lemmens. (2004) Leopards in the Temple: Restoring Scientific Integrity to the Commercialized Research Scene. The Journal of Law, Medicine & Ethics 32:4, 641-657
CrossRef162
E. J. Begg. (2004) Individualizing drug therapy, and 'men behaving badly'. British Journal of Clinical Pharmacology 58:5, 449-451
CrossRef163
E. Haavi Morreim. (2004) Beyond the Lies: Solving the Problem. The American Journal of Bioethics 4:4, 61-63
CrossRef
- Letters
